New formulation allows twice-daily dosing in patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate, or sickle cell disease or other anemias. BOSTON, March 31, 2023 /PRNewswire/ — Chiesi Global Rare Diseases, a business unit of… Click here to view original post… […]
As maternity wards continue to close around the country, some states are implementing “bold and innovative” solutions—though none that will be as effective as federal intervention, according to Harvard Chan School’s Alecia McGregor. Click here to view original post… […]
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.–(BUSINESS WIRE)—- $IMV #CancerVaccine–IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the “Company”)… Click here to view original post… […]
The massive new complex that MGH is building on Charles Street will be named after InterSystems founder Phillip Ragon and his wife, Susan, the hospital said Friday. Click here to view original post… […]
CONCORD, Mass., March 31, 2023 /PRNewswire/ — Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced that Scott Megaffin, Chief Executive… Click here to view original post… […]
As clinicians work to meet demand amid workforce shortages, a new study suggests that some patients don’t need to be there in the first place. Click here to view original post… […]
MIT researchers built DiffDock, a model that may one day be able to find new drugs faster than traditional methods and reduce the potential for adverse side effects. Click here to view original post… […]
Researchers develop new, patient-friendly hydrogel platform for administering lifesaving biologics. Click here to view original post… […]
Jim Mullen is in, by his count, his third or fourth “long, cold winter in biotech investing.” But that’s not stopping the ex-Biogen CEO from finding flickers of light. Jim Mullen Earlier this week, private equity player Advent International announced that Mullen had joined as… Click here to view original post… […]
The FDA approved, Narcan, a medicine that can reverse opioid-related overdoses, for over the counter use this week. State health officials are calling on insurers to continue covering the medicine. Click here to view original post… […]
Copyright © 2023 Biotech Networks, LLC
